AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice
Journal article
Shamshoum, Hesham, Medak, Kyle D., Townsend, Logan K., Ashworth, Kristen E., Bush, Natasha D., Halm, Margaret K., Kemp, Bruce E. and Wright, David C.. (2019). AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice. The FASEB Journal. 33(12), pp. 14010-14021. https://doi.org/10.1096/fj.201901820R
Authors | Shamshoum, Hesham, Medak, Kyle D., Townsend, Logan K., Ashworth, Kristen E., Bush, Natasha D., Halm, Margaret K., Kemp, Bruce E. and Wright, David C. |
---|---|
Abstract | Olanzapine (OLZ) is a second-generation antipsychotic that is used to treat schizophrenia but also causes acute hyperglycemia. This study aimed to determine if the ablation of AMPK β1-containing complexes potentiates acute OLZ-induced metabolic dysfunction and if the activation of AMPK β1 suppresses these effects. Female AMPK β1-/- or wild-type (WT) control mice were treated with OLZ, and changes in bloodglucose, serum and liver metabolites, whole-body fuel oxidation, and pyruvate-induced increases in blood glucose were measured. Additionally, WT mice were cotreated with OLZ and A769662, a specific AMPK β1 activator, and we determined if cotreatment protected against acute, OLZ-induced metabolic dysfunction. OLZ-induced increases in blood glucose were exacerbated in AMPK β1-/- mice compared with WT mice, and this was paralleled by greater OLZ-induced increases in markers of liver glucose production, such as pyruvate tolerance, serum glucagon, and glucagon responsiveness. Cotreatment with A769662 attenuated OLZ-induced increases in blood glucose, serum nonesterified fatty acid, and glycerol. Furthermore, this effect was absent in AMPK β1-/- mice, consistent with A769662's specificity for the AMPK β1 subunit. Reductions in AMPK activity potentiate the effects of acute OLZ treatment on blood glucose, whereas specifically targeting AMPK β1-containing complexes is sufficient to protect against OLZ-induced hyperglycemia.—Shamshoum, H., Medak, K. D., Townsend, L. K., Ashworth, K. E., Bush, N. D., Hahn, M. K., Kemp, B. E., Wright, D. C. AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice. |
Keywords | olanzapine; A769662; liver; glucose; lipids |
Year | 2019 |
Journal | The FASEB Journal |
Journal citation | 33 (12), pp. 14010-14021 |
Publisher | Federation of American Societies for Experimental Biology |
ISSN | 0892-6638 |
Digital Object Identifier (DOI) | https://doi.org/10.1096/fj.201901820R |
Scopus EID | 2-s2.0-85076123780 |
Research or scholarly | Research |
Page range | 14010-14021 |
Funder | Australian Research Council (ARC) |
National Health and Medical Research Council (NHMRC) | |
Publisher's version | License All rights reserved File Access Level Controlled |
Output status | Published |
Publication dates | |
Online | 03 Oct 2019 |
Publication process dates | |
Accepted | 10 Sep 2019 |
Deposited | 21 Dec 2021 |
ARC Funded Research | This output has been funded, wholly or partially, under the Australian Research Council Act 2001 |
Grant ID | ARC/DP170101196 |
NHMRC/1085460 |
https://acuresearchbank.acu.edu.au/item/8x3vy/ampk-1-activation-suppresses-antipsychotic-induced-hyperglycemia-in-mice
Restricted files
Publisher's version
82
total views0
total downloads0
views this month0
downloads this month